PT-141 peptide nasal spray for women is a research-only form of bremelanotide. Learn how it works, dosage questions, safety, and legal status in the US.
PT-141 peptide nasal spray for women is not FDA-approved for any use in the United States. The only FDA-approved form of PT-141 (bremelanotide) is a subcutaneous injection sold as Vyleesi, and it is approved specifically for premenopausal women with hypoactive sexual desire disorder (HSDD). Nasal spray products sold online are unapproved research chemicals, not verified medications.
What Is PT-141 Peptide Nasal Spray?
PT-141 is the research name for bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain. Scientists originally studied it for tanning, but clinical trials revealed it could increase sexual desire. The FDA approved the injectable form in 2019 for premenopausal women with HSDD.
The nasal spray is a different delivery method. Instead of injecting the peptide under the skin, a user sprays it into the nose, hoping it reaches the bloodstream through the nasal lining. No nasal bremelanotide product has been approved by the FDA for women or men.
Research on intranasal bremelanotide exists, but it is early and limited. Most of it comes from small studies or animal models. That means claims about how well a nasal spray works for women are not backed by large, controlled human trials.
Why Some Women Look at the Nasal Spray Form
The main appeal of a nasal spray is avoiding needles. Injections can be uncomfortable, and some women dislike self-injecting. A spray sounds easier and more discreet.
Another reason is speed. Some people believe nasal delivery works faster than an injection, but that has not been proven for PT-141 in women. The pharmacokinetics of nasal bremelanotide in humans are not well characterized.
PT-141 is also studied in men. If you have seen discussions about pt-141 peptide nasal spray for men, keep in mind that male-focused dosing and results do not automatically apply to women. Hormones, body composition, and sexual response systems differ.
PT-141 Nasal Spray vs. FDA-Approved Bremelanotide Injection
The table below compares the unapproved nasal spray with the prescription injection. This is not a recommendation, only a factual comparison.
| Feature | PT-141 Nasal Spray (Research) | Bremelanotide Injection (Vyleesi) |
|---|---|---|
| FDA approval | Not approved | Approved for premenopausal women with HSDD |
| Route | Intranasal | Subcutaneous injection |
| Standard dose | Not established | 1.75 mg as needed, at least 45 minutes before sex, max once per 24 hours and no more than 8 doses per month |
| Common side effects | Unknown; possible nasal irritation, bleeding, or systemic effects | Nausea, flushing, headache, injection site reactions, vomiting |
| Availability | Research chemical websites | Prescription pharmacy |
| Legal status | Not legal to sell as a drug for human use | Prescription only |
| Quality control | Unregulated; purity and sterility not guaranteed | Regulated by FDA |
Dosage and Safety: What Is Known and Unknown
There is no established safe or effective nasal spray dose of PT-141 for women. Studies that used intranasal bremelanotide have varied widely in dose and formulation, and none led to an approved product.
Some online sellers suggest doses, but those numbers are not based on FDA-reviewed data. Dosing information, including pt-141 nasal spray dosage for men, cannot be directly transferred to women because safety and efficacy have not been compared.
Known risks of bremelanotide in general include nausea, flushing, headache, and temporary increases in blood pressure. The injection carries a warning about focal hyperpigmentation, especially with frequent use. Nasal sprays could theoretically cause nasal irritation, nosebleeds, or altered absorption if the nasal lining is damaged.
People with uncontrolled high blood pressure, known cardiovascular disease, or a history of heart attack or stroke should not use bremelanotide. Anyone who is pregnant, breastfeeding, or taking other medications should avoid it unless a doctor says otherwise.
PT-141 nasal spray is not a proven treatment for low sexual desire in women, and no nasal product has passed FDA review for safety or effectiveness.
Legal and Regulatory Status of Nasal PT-141
The FDA has not approved any nasal spray containing bremelanotide. Selling a nasal spray as a drug for human use without approval is illegal in the United States. Many vendors get around this by labeling their products as "research chemicals" or "not for human consumption."
When you see pt-141 peptide nasal spray for sale on a research site, you cannot assume the product is pure, sterile, or even contains the correct peptide. Independent testing has found that many research chemicals are mislabeled or contaminated.
Online pt-141 peptide nasal spray reviews are anecdotal. They may describe a placebo effect, a mild reaction, or a negative experience, but they are not clinical evidence. You will not find pt-141 peptide nasal spray amazon listings because Amazon prohibits the sale of unapproved drugs and many research chemicals.
Shoppers looking at unapproved nasal PT-141 online should also know that importing unapproved drugs can lead to seizure by customs. Legitimate pharmacies will not sell nasal PT-141 without a prescription, and no such prescription product exists.
What to Do If You Are Considering PT-141 for Low Desire
Low sexual desire can have many causes, including stress, relationship issues, medications, hormonal changes, and medical conditions. A healthcare professional can help identify the cause and discuss approved options.
If you are premenopausal and have HSDD, the FDA-approved bremelanotide injection may be an option. Your doctor can explain the risks, benefits, and cost. For postmenopausal women or other groups, bremelanotide is not approved, and use would be off-label.
Do not buy nasal PT-141 from an unregulated website and use it without medical supervision. The dose is unknown, the product quality is uncertain, and serious side effects are possible.
Women with concerns about sexual desire should talk with a licensed healthcare professional before trying any form of PT-141.
Frequently Asked Questions
Is PT-141 nasal spray FDA-approved for women?
No. The FDA has approved only bremelanotide injection (Vyleesi) for premenopausal women with hypoactive sexual desire disorder. No nasal spray form of PT-141 is approved for any population.
Does PT-141 nasal spray work for women?
There is no strong clinical evidence that nasal PT-141 improves sexual desire in women. Small, early studies do not confirm effectiveness, and unregulated products may not contain what they claim.
Where can I buy PT-141 nasal spray for women?
You cannot legally buy an FDA-approved nasal PT-141 product because none exists. Research chemical websites sell unapproved versions, but those products are not verified for safety, purity, or dose, and buying them carries legal and health risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.